Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.veinsensor.pl
Are you over 18 and want to see adult content?
A complete backup of 131458934.keywordblocks.com
Are you over 18 and want to see adult content?
A complete backup of markkavanagh.com
Are you over 18 and want to see adult content?
A complete backup of azscers.000webhostapp.com
Are you over 18 and want to see adult content?
A complete backup of abc12.onesignal.com
Are you over 18 and want to see adult content?
A complete backup of sp-active.adsrvr.org
Are you over 18 and want to see adult content?
A complete backup of services.runescape.com-api.top
Are you over 18 and want to see adult content?
A complete backup of cb1.dev.rtb.owneriq.net
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of greensyssolutions.com
Are you over 18 and want to see adult content?
A complete backup of polerasestampadas.cl
Are you over 18 and want to see adult content?
A complete backup of feriendorf-gross-vaeter-see.de
Are you over 18 and want to see adult content?
A complete backup of famysiraso.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of raquelsantos92.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of sietediasmedicos.com
Are you over 18 and want to see adult content?
A complete backup of amorimlima.org.br
Are you over 18 and want to see adult content?
Text
Meeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Sphingolipid activator protein, SapC 80 amino acids, 9kDA Fermentation and Purification - rDNA, e. Coli Sphingolipids - contribute to regulation of cell membrane bilayers Bioactive sphingolipids (like ceramide) PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels thatCLINICAL TRIALS
BXQ-350 Clinical Trial Update Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the UnitedEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
CINCINNATI ENQUIRER: 8 CINCINNATI BIOTECH COMPANIES WITH Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a year. In alphabetical order, HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Sphingolipid activator protein, SapC 80 amino acids, 9kDA Fermentation and Purification - rDNA, e. Coli Sphingolipids - contribute to regulation of cell membrane bilayers Bioactive sphingolipids (like ceramide) PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels thatCLINICAL TRIALS
BXQ-350 Clinical Trial Update Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the UnitedEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
CINCINNATI ENQUIRER: 8 CINCINNATI BIOTECH COMPANIES WITH Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a year. In alphabetical order, RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activationCLINICAL TRIALS
BXQ-350 Clinical Trial Update Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the UnitedEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy LEADERSHIP | BEXION PHARMACEUTICALS A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positionedSAFE HARBOR
This Web site contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections of events, revenues, income, future economic, research, development, reformulation, product performance or management’s plans and objectives for future operations. In some cases you RICHARD J. SCHWEN, PHD, DABT, RAC Richard J. Schwen, PhD, DABT, RAC Regulatory Consultant Dr. Richard Schwen has over 35 years’ experience as a regulatory and toxicology expert and senior manager in the pharmaceutical industry. Prior management experience includes Vice President positions at Kendle International, PAREXEL International, and Ausio Pharmaceuticals in the areas of regulatory affairs, safety and compliance. MARGARET VAN GILSE, M.B.A. VICE PRESIDENT, BUSINESS Margaret van Gilse, M.B.A. Business Development Previously was Vice President, Business Development for PrimeDP, a global drug development consulting company, where she supported life science projects and product registrations, and managed local and regional government and business relations. Ms. van Gilse has over 25 years of business development, strategic planning and fund-raising CL (ML/H/KG) 68.38 61.78±18.3474.44±19.5676.29±6.71 48.39 2/12/2019 Submission Completed https://asco.confex.com/asco/2019/sci/papers/index.cgi?username=264735&password=539708 2/5 First Author Presenting Author 2/12/2018 SUBMISSION COMPLETED 2/12/2018 Submission Completed https://asco.confex.com/asco/2018/sci/papers/index.cgi?username=217541&password=441061 1/5 Your abstract submission has been received HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Sphingolipid activator protein, SapC 80 amino acids, 9kDA Fermentation and Purification - rDNA, e. Coli Sphingolipids - contribute to regulation of cell membrane bilayers Bioactive sphingolipids (like ceramide) PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
EXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Sphingolipid activator protein, SapC 80 amino acids, 9kDA Fermentation and Purification - rDNA, e. Coli Sphingolipids - contribute to regulation of cell membrane bilayers Bioactive sphingolipids (like ceramide) PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
EXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
EXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available.CASE STUDIES
Case Studies Case Data: Glioblastoma (GBM) Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is BEXION PHARMACEUTICALS ANNOUNCES DATABASE LOCK IN PHASE 1 FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome’s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients NEW SEGMENT OF ADVANCEMENTS TO FOCUS ON BREAKTHROUGHS IN Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases CLINICAL ADVISORY BOARD Clinical Advisory Board Manmeet Ahluwalia, MD, FACP Dean and Diane Miller Family Endowed Chair in Neuro-Oncology Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio Timothy P. Cripe, MD, PhD, FAAP Chief of the Division of Hematology and Oncology Gordon Teter Endowed Chair in Pediatric Cancer Nationwide Children’s CL (ML/H/KG) 68.38 61.78±18.3474.44±19.5676.29±6.71 48.39 2/12/2019 Submission Completed https://asco.confex.com/asco/2019/sci/papers/index.cgi?username=264735&password=539708 2/5 First Author Presenting Author HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapyEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapyEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
MEDIA & PRESS
FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapyCLINICAL TRIALS
BXQ-350 Clinical Trial Update Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the UnitedEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. BEXION PHARMACEUTICALS ANNOUNCES DATABASE LOCK IN PHASE 1 FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome’s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patients NEW SEGMENT OF ADVANCEMENTS TO FOCUS ON BREAKTHROUGHS IN Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases MARGARET VAN GILSE, M.B.A. VICE PRESIDENT, BUSINESS Margaret van Gilse, M.B.A. Business Development Previously was Vice President, Business Development for PrimeDP, a global drug development consulting company, where she supported life science projects and product registrations, and managed local and regional government and business relations. Ms. van Gilse has over 25 years of business development, strategic planning and fund-raising CL (ML/H/KG) 68.38 61.78±18.3474.44±19.5676.29±6.71 48.39 2/12/2019 Submission Completed https://asco.confex.com/asco/2019/sci/papers/index.cgi?username=264735&password=539708 2/5 First Author Presenting Author HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activationEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
LEADERSHIP | BEXION PHARMACEUTICALS A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activationEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
LEADERSHIP | BEXION PHARMACEUTICALS A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
MEDIA & PRESS
FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapyCLINICAL TRIALS
BXQ-350 Clinical Trial Update Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the UnitedEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. BEXION PHARMACEUTICALS ANNOUNCES DATABASE LOCK IN PHASE 1 FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome’s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patientsCASE STUDIES
Case Studies Case Data: Glioblastoma (GBM) Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is NEW SEGMENT OF ADVANCEMENTS TO FOCUS ON BREAKTHROUGHS IN Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases CL (ML/H/KG) 68.38 61.78±18.3474.44±19.5676.29±6.71 48.39 2/12/2019 Submission Completed https://asco.confex.com/asco/2019/sci/papers/index.cgi?username=264735&password=539708 2/5 First Author Presenting Author HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
EXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LEADERSHIP | BEXION PHARMACEUTICALSBEXION PHARMABEXION PHARMACEUTICALSJOBSBEXION TRIAL
A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
ABOUT BEXION
Identifying and Developing Breakthrough Medicines Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
EXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LEADERSHIP | BEXION PHARMACEUTICALSBEXION PHARMABEXION PHARMACEUTICALSJOBSBEXION TRIAL
A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
MEDIA & PRESS
FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May BEXION PHARMACEUTICALS, INC. TO PRESENT AT THE 2021 FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT Annual Meeting connects the global cancer immunotherapyEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. BEXION PHARMACEUTICALS ANNOUNCES DATABASE LOCK IN PHASE 1 FOR IMMEDIATE RELEASE Covington, KY, December 10, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotech company focused on the discovery and development of life-changing treatments by leveraging the lysosome’s roles in solid tumors and cell death with an initial focus on cancer, announced today the database lock for the Phase 1 study of BXQ-350 in adult patientsCASE STUDIES
Case Studies Case Data: Glioblastoma (GBM) Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is NEW SEGMENT OF ADVANCEMENTS TO FOCUS ON BREAKTHROUGHS IN Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases CLINICAL ADVISORY BOARD Clinical Advisory Board Manmeet Ahluwalia, MD, FACP Dean and Diane Miller Family Endowed Chair in Neuro-Oncology Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC) Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio Timothy P. Cripe, MD, PhD, FAAP Chief of the Division of Hematology and Oncology Gordon Teter Endowed Chair in Pediatric Cancer Nationwide Children’s CL (ML/H/KG) 68.38 61.78±18.3474.44±19.5676.29±6.71 48.39 2/12/2019 Submission Completed https://asco.confex.com/asco/2019/sci/papers/index.cgi?username=264735&password=539708 2/5 First Author Presenting Author HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activationEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
LEADERSHIP | BEXION PHARMACEUTICALSBEXION PHARMABEXION PHARMACEUTICALSJOBSBEXION TRIAL
A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned HOME | BEXION PHARMACEUTICALSPLATFORMPIPELINECLINICAL TRIALSRESOURCESABOUT BEXIONCONTACT April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
PLATFORM | BEXION PHARMACEUTICALS Turning a Lysosomal Protein into a Drug: BXQ-350 Active agent is the Lysosomal Protein Saposin C Fusogenic to Phosphatidylserine The Promise of BXQ-350 Need SapC graphic/text Need normal/tumor graphic Beyond a stress response PS is immunosuppressive BXQ-350 Anti-Cancer Properties Need anti-cancer properties graphic PLATFORM | BEXION PHARMACEUTICALS The Promise of BXQ-350. BXQ-350 possesses tumor agnostic properties and represents a paradigm shift in the fight against cancer. Utilizing a small lysosomal protein known as Saposin C with a lipid, BXQ-350 targets both externalized phosphatidylserine and tumor lysosomes to initiate tumor cell death. In tumor cells and the blood vessels that PIPELINE | BEXION PHARMACEUTICALS BXQ-350, An Innovative Asset With Potential For Multiple Indications BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a criticalneed for new, safe
RESOURCES | BEXION PHARMACEUTICALS Resources Posters A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors > View BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activationEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
RAY TAKIGIKU, PH.D. PRESIDENT AND CEO Ray Takigiku, Ph.D. President and CEO Ray Takigiku, PhD is the founder of Bexion Pharmaceuticals, an oncology-focused company with a novel compound in clinical development for solid tumors, including DIPG/DMG a rare brain tumor. Ray is an entrepreneurial life scientist with over 30 years of experience in the discovery, development, and marketsupport of
LEADERSHIP | BEXION PHARMACEUTICALSBEXION PHARMABEXION PHARMACEUTICALSJOBSBEXION TRIAL
A Leadership Team with Unique and Complementary Skills Bexion Pharmaceuticals’ leadership team has extensive experience across all facets of pharmaceutical operations including discovery, research and development, manufacturing, clinical, regulatory, and commercialization. With a proven track record of success in bringing life-changing treatments to market, we are well positioned HOME - NEW | BEXION PHARMACEUTICALS April 20, 2021. FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually May 10-12, 2021 has been chosen for presentation. Every year, the CIMT AnnualMeeting
MEDIA & PRESS
FOR IMMEDIATE RELEASE Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced today that an abstract submitted for an eTalk Session at the CIMT annual meeting to be held virtually MayEXPANDED ACCESS
Expanded Access. Expanded access (sometimes referred to as compassionate use) is a potential pathway for patients with a serious or immediately life-threatening disease or condition to gain access to an investigational medicine outside of a clinical trial when no other treatment options are available. LYSOSOME | BEXION PHARMACEUTICALS Lysosome The Lysosome – A Crucial Cellular Orchestrator. The Lysosome is an Underexploited Cellular Orchestrator Often called the "stomach of the cell", lysosomes digest and recycle internal and external molecules, like waster minerals and cellular debris. 1955: Lysosome described by Christian de Duve, terming them "suicide bags"for
SAFE HARBOR
This Web site contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections of events, revenues, income, future economic, research, development, reformulation, product performance or management’s plans and objectives for future operations. In some cases you NEW SEGMENT OF ADVANCEMENTS TO FOCUS ON BREAKTHROUGHS IN Jupiter, FL— The award-winning series, Advancements with Ted Danson, will focus on an innovative, targeted approach to treating a range of diseases during 3Q/2021. Check local listings for more information. The diseases for which medicine offers few effective options – advanced cancer (or even early-stage cancer for certain types), neurodegenerative diseases and autoimmune diseases HIGH MARKET POTENTIAL High Market Potential. GBM is a very aggressive brain tumor. Bexion is currently pursuing cancer treatments where there is a significant unmet need and high market potential*. Stage 4 colorectal cancer 5-year survival rate is between 11 and 14%. GBM average survival is 16-20 months, with only 25% of glioblastoma patients surviving 2years.
GILLES TAPOLSKY, PHD, MBA Gilles Tapolsky, PhD, MBA Pharmacology Dr. Gilles Tapolsky has over thirty years in the areas of preclinical and clinical drug development. Gilles has worked for both large international and emerging biotech companies. His experience includes drug discovery, R&D and translational research, preclinical studies, pharmaceutical development, CMC and clinical development. He has submitted multiple RICHARD J. SCHWEN, PHD, DABT, RAC Richard J. Schwen, PhD, DABT, RAC Regulatory Consultant Dr. Richard Schwen has over 35 years’ experience as a regulatory and toxicology expert and senior manager in the pharmaceutical industry. Prior management experience includes Vice President positions at Kendle International, PAREXEL International, and Ausio Pharmaceuticals in the areas of regulatory affairs, safety and compliance. MARGARET VAN GILSE, M.B.A. VICE PRESIDENT, BUSINESS Margaret van Gilse, M.B.A. Business Development Previously was Vice President, Business Development for PrimeDP, a global drug development consulting company, where she supported life science projects and product registrations, and managed local and regional government and business relations. Ms. van Gilse has over 25 years of business development, strategic planning and fund-raising 632 Russell Street, Covington, KY 41011Facebook Twitter
* HOME
* ABOUT __
* HISTORY
* MANAGEMENT TEAM
* BOARD OF DIRECTORS * SCIENTIFIC ADVISORY BOARD* PARTNERSHIPS
* CLINICAL TRIALS
* TECHNOLOGY
* INVESTORS
* MEDIA __
* MEDIA COVERAGE
* NEWSLETTER
* PRESS RELEASES
* CONTACT
* HOME
* ABOUT
* HISTORY
* MANAGEMENT TEAM
* BOARD OF DIRECTORS * SCIENTIFIC ADVISORY BOARD* PARTNERSHIPS
* CLINICAL TRIALS
* TECHNOLOGY
* INVESTORS
* MEDIA
* MEDIA COVERAGE
* NEWSLETTER
* PRESS RELEASES
* CONTACT
*
POWER BY NATURE. PRECISION BY SCIENCE. ™*
*
WELCOME admin
2017-11-20T20:36:25+00:00admin
2019-09-06T14:38:50+00:00 BEXION PHARMACEUTICALS, INC. TO PRESENT CLINICAL DATA AT 2019 NORDANNUAL MEETING
admin
2019-09-06T14:38:50+00:00 September 4th, 2019|0 Comments Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical companyfocused on
admin
2019-08-13T12:09:47+00:00 SIGNIFICANT REGULATORY MILESTONE TOWARDS PHASE 2 IN RECURRENT GBMadmin
2019-08-13T12:09:47+00:00 July 30th, 2019|0 Comments FOR IMMEDIATE RELEASE Covington, KY ~ 30 July 2019 Bexion Pharmaceuticals, Inc. an oncology-focused company today announced the completion of a Type B End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) toadmin
2019-05-31T23:28:50+00:00 KY INNOVATION, THE STATE’S ENTREPRENEURSHIP AND INNOVATION ENTERPRISE, RECENTLY LAUNCHED A NEW WEBSITEadmin
2019-05-31T23:28:50+00:00 May 31st, 2019|0 Comments KY Innovation, the state’s entrepreneurship and innovation enterprise, recently launched a new website. Bexion is honored to be chosen as the model business at the intersection of innovation and public good. Please click on the BEXION PHARMACEUTICALS IS DEVELOPING INNOVATIVE CURES FOR CANCER. UNLIKE ANY OTHER POTENTIAL DRUG KNOWN IN DEVELOPMENT, BXQ-350 HAS AN ENTIRELY NEW AND NOVEL MECHANISM OF ACTION. Read More About BexionCLINICAL TRIALS
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma). Information about the PHASE 1 STUDY OF BXQ-350 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS trial can be found at https://www.clinicaltrials.gov/show/NCT02859857 copyright 2018. All Rights Reserved. Bexion Pharmaceuticals | 632 Russell Street Covington, KY41011
Terms of Use | Safe Harbor| Privacy Policy
Facebook Twitter
Go to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0